Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor
(selective inhibitor of nuclear export) in combination with standard therapy for B cell
Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose
of Selinexor in combination with RCHOP and also study the efficacy of this combination for
therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better
in treating patients with B cell non-Hodgkin lymphoma.